Overdose Risk Management and Naloxone

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

August 1, 2022

Study Completion Date

August 31, 2023

Conditions
Opioid Use
Interventions
OTHER

Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.

At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.

Trial Locations (2)

10001

RECRUITING

270 West 25th Street, New York

10010

RECRUITING

National Development and Research Institutes, Inc., New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brandeis University

OTHER

collaborator

Drexel University

OTHER

collaborator

New York University

OTHER

collaborator

Rhode Island Hospital

OTHER

lead

National Development and Research Institutes, Inc.

OTHER

NCT03933345 - Overdose Risk Management and Naloxone | Biotech Hunter | Biotech Hunter